NCT06127940View on ClinicalTrials.gov

K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 15, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

January 1, 2026

Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
RADIATION

Stereotactic body radiation therapy (SBRT)

SBRT is delivered using institutional standard dosing while sotorasib is withheld during radiation.

DRUG

Temporary Stopping

Temporary stop of sotorasib during SBRT

Trial Locations (1)

17176

RECRUITING

Karolinska University Hospital, Stockholm

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Amgen

INDUSTRY

lead

Karolinska University Hospital

OTHER

NCT06127940 - K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation | Biotech Hunter | Biotech Hunter